Anticipation Rises for Clinical Batch Opportunities from Latecomer Developers
Macrogen, ST Pharm, Pamcil, NIBEC
Equipped with Key Technologies in Analysis, Raw Materials, Manufacturing, and Delivery

Following the news of the successful phase 3 clinical trial of the messenger ribonucleic acid (mRNA) cancer vaccine developed by Moderna and Merck & Co. (MSD) of the United States, attention in the domestic market toward Korean bio companies has surged dramatically. This is fueled by expectations that the production method of this vaccine will create new demand for domestic gene analysis and mRNA companies.


K-Bio Stirred by mRNA Cancer Vaccine...Will New 'Opportunities' Open? View original image

While the possibility of immediate contract orders is limited, given that Moderna has internalized most of its processes, there is anticipation that opportunities could arise first in relation to clinical orders from other developers who will follow in Moderna's footsteps.


According to the bio industry on August 21, as patient gene analysis and mRNA manufacturing and delivery technology are being highlighted as core technologies for personalized cancer vaccines that reduce the risk of relapse in cancer patients, several domestic bio-technology firms equipped with these capabilities are drawing attention. Some companies even closed at the upper limit of their stock price on August 20, the day the news of Moderna's clinical success was announced.


K-Bio Stirred by mRNA Cancer Vaccine...Will New 'Opportunities' Open? View original image

One company garnering attention is Macrogen, a gene analysis subcontractor. Macrogen could be responsible for gene sequencing—the first stage in vaccine design. Now that the clinical trial results have demonstrated the viability of personalized cancer vaccines, it is expected that if this approach spreads to other diseases, demand for gene sequencing from both domestic and foreign companies could increase significantly.


ST Pharm is also considered a beneficiary because it possesses the capability to directly manufacture mRNA and its own capping technology. mRNA generates impurities during the synthesis process, and if these are not adequately filtered out, the immune system may respond incorrectly, or the necessary proteins may not be produced in sufficient quantities. The purity of the mRNA is thus essential for the drug’s safety and efficacy.


ST Pharm’s capping technology, known as 'SmartCap,' attaches a protective structure to one end of the mRNA, helping the mRNA avoid rapid degradation in the body and allowing it to produce proteins effectively. As personalized cancer vaccine development becomes more widespread, demand for such high-quality mRNA production technologies is expected to rise.


Pamgene, a prominent player in the production of nucleosides—the raw materials used in mRNA synthesis—is also receiving attention. Nucleosides are the fundamental building blocks of mRNA. Pamgene also produces components of the carriers that encapsulate the mRNA, and is thus positioned to become a core 'material supplier' in the development of mRNA pharmaceuticals.


The carrier technology that delivers mRNA to target sites within the body is also seen as a critical factor in the commercialization of personalized cancer vaccines. In Korea, NIBEC owns such carrier technology. Since mRNA, when injected directly, is easily degraded, it needs to be encapsulated and transported to the cells; currently, lipid nanoparticles (LNP) are the standard delivery method.


Current commercialized LNP technologies, including those owned by Moderna, have not yet reached the level of selectively targeting specific tissues. In the case of vaccines, it is particularly important that the delivery vehicle precisely reaches the lymph nodes, where immune cells congregate, because efficacy and side effects are both determined by the targeting performance of the carrier. NIBEC is developing a peptide-based alternative carrier to address this need.



While the issue of achieving robust intracellular expression of mRNA has been largely resolved, precisely controlling its destination remains a challenge. As personalized vaccines expand to cover various cancers, demand for more precise targeted delivery is expected to grow, resulting in increased interest in alternative carriers to replace existing LNP technology.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing